nach oben

10.02.2024 | Original Article

Changes in serum levels of liver-related parameters, uric acid, and hemoglobin in patients with type 2 diabetes mellitus under treatment with tofogliflozin—a post-hoc analysis of the UTOPIA study

verfasst von: Naoto Katakami, Tomoya Mita, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura

Erschienen in: Diabetology International

Einloggen, um Zugang zu erhalten

Abstract

Aims/Introduction

The aim of the study was to evaluate the effects of tofogliflozin, a selective sodium-glucose cotransporter 2 inhibitor, on circulating levels of hepatic enzymes, uric acid and hemoglobin levels in patients with type 2 diabetes mellitus (T2DM).

Materials and methods

We evaluated longitudinal changes in circulating aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (γ-GTP), uric acid, and hemoglobin levels in tofogliflozin (n = 169) and conventional treatment groups (n = 170) using data obtained from the UTOPIA trial, a randomized prospective study conducted to evaluate the efficacy of tofogliflozin in preventing atherosclerosis.

Results

Within 104 weeks, tofogliflozin treatment, but not conventional treatment, significantly reduced AST, ALT, and γ-GTP levels. This reduction was significantly greater in the tofogliflozin group than in the conventional group. Stratified analysis showed that, in patients with obesity (defined as body mass index (BMI) ≥ 25.0 kg/m²), significant differences were observed in AST, ALT, and γ-GTP changes from baseline to 104 weeks between treatment groups. However, in patients without obesity, there were no significant differences in AST and γ-GTP changes from baseline to 104 weeks between treatment groups. Multivariable regression analysis showed that changes in BMI and HbA1c levels were independently associated with changes in AST, ALT, and γ-GTP levels. The reduction of uric acid and the increase of hemoglobin from baseline to 104 weeks were significantly greater in the tofogliflozin group than in the conventional group.

Conclusions

The beneficial effects of tofogliflozin on circulating levels of hepatic enzymes, uric acid, and Hb lasted for 2 years in patients with T2DM.

Clinical trial registration

UMIN000017607 (https://www.umin.ac.jp/icdr/index.html)

Nur mit Berechtigung zugänglich

Kashiwagi A, Maegawa H. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus. J Diabetes Investig. 2017;8:416–27.CrossRefPubMedPubMedCentral

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:211721–8.CrossRef

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, CANVAS Program Collaborative Group, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.CrossRefPubMed

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–57.CrossRefPubMed

Leiter LA, Forst T, Polidori D, Balis DA, Xie J, Sha S. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab. 2016;42(1):25–32.CrossRefPubMed

Ito D, Shimizu S, Inoue K, Saito D, Yanagisawa M, Inukai K, et al. Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care. 2017;40(10):1364–72.CrossRefPubMed

Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care. 2018;41(8):1801–8.CrossRefPubMed

Lee PCH, Gu Y, Yeung MY, Fong CHY, Woo YC, Chow WS, et al. Dapagliflozin and empagliflozin ameliorate hepatic dysfunction among Chinese subjects with diabetes in part through glycemic improvement: a single-center, retrospective, observational study. Diabetes Ther. 2018;9:285–95.CrossRefPubMedPubMedCentral

Shimizu M, Suzuki K, Kato K, Jojima T, Iijima T, Murohisa T, et al. Evaluation of the effects of dapagliflozin, a sodiumglucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019;21(2):285–92.CrossRefPubMed

10.

Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589–600. https://doi.org/10.1016/j.jhep.2016.05.01.CrossRefPubMed

11.

Mantovani A, Zaza G, Byrne CD, Lonardo A, Zoppini G, Bonora E, et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis. Metabolism. 2018;79:64–76. https://doi.org/10.1016/j.metabol.2017.11.003.CrossRefPubMed

12.

Eslam M, Sanyal AJ, George J. the International consensus panel collaborators. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999–2014.CrossRefPubMed

13.

Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nation-wide cohort study. Clin Gastroenterol Hepatol. 2021;19:2138–47.CrossRefPubMed

14.

Zhao Y, Xu L, Tian D, Xia P, Zheng H, Wang L, Chen L. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2018;20:458–62.CrossRefPubMed

15.

Reaven GM. The kidney: an unwilling accomplice in syndrome X. Am J Kidney Dis. 1997;30:928–31.CrossRefPubMed

16.

Kanbay M, Jensen T, Solak Y, Le M, Roncal-Jimenez C, Rivard C, et al. Uric acid in metabolic syndrome: from an innocent bystander to a central player. Eur J Intern Med. 2016;29:3–8.CrossRefPubMed

17.

Yuan H, Yu C, Li X, Sun L, Zhu X, Zhao C, et al. Serum uric acid levels and risk of metabolic syndrome: a dose-response meta-analysis of prospective studies. J Clin Endocrinol Metab. 2015;100:4198–207.CrossRefPubMed

18.

Zoppini G, Targher G, Chonchol M, Ortalda V, Abaterusso C, Pichiri I, et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care. 2012;35:99–104.CrossRefPubMed

19.

Tsai CW, Lin SY, Kuo CC, Huang CC. Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLoS One. 2017;12:e0170393.CrossRefPubMedPubMedCentral

20.

Kim IY, Lee DW, Lee SB, Kwak S. The role of uric acid in kidney fibrosis: experimental evidences for the causal relationship. BioMed Res Int. 2014;2014:638732. https://doi.org/10.1155/2014/638732.CrossRefPubMedPubMedCentral

21.

Bailey CJ, Iqbal N, T’Joen C, List JF. Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab. 2012;14:951–9.CrossRefPubMed

22.

Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, et al. EMPA-REG PIO™ trial investigators. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014;16:147–58.CrossRefPubMed

23.

Maruyama T, Takashima H, Oguma H, Nakamura Y, Ohno M, Utsunomiya K, et al. Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease. Diabetes Technol Ther. 2019;21:713–20.CrossRefPubMedPubMedCentral

24.

Kanbay M, Tapoi L, Ureche C, Tanriover C, Cevik E, Demiray A, et al. Effect of sodium-glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis. Int Urol Nephrol. 2022;54:827–41. https://doi.org/10.1007/s11255-021-02943-2.CrossRefPubMed

25.

Suzuki M, Honda K, Fukazawa M, Ozawa K, Hagita H, Kawai T, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012;341:692–701.CrossRefPubMed

26.

Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K, Tofogliflozin 003 Study Group, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014;13:65.CrossRefPubMedPubMedCentral

27.

Tanizawa Y, Kaku K, Araki E, Tobe K, Terauchi Y, Utsunomiya K, Tofogliflozin 004 and 005 Study group, et al. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother. 2014;15(6):749–66.CrossRefPubMed

28.

Takeshita Y, Honda M, Harada K, Kita Y, Takata N, Tsujiguchi H, et al. Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial. Diabetes Care. 2022;45(9):2064–75.CrossRefPubMedPubMedCentral

29.

Utsunomiya K, Shimmoto N, Senda M, Kurihara Y, Gunji R, Fujii S, et al. Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: a post-marketing study (J-STEP/EL Study). J Diabetes Investig. 2017;8:766–75.CrossRefPubMedPubMedCentral

30.

Utsunomiya K, Kakiuchi S, Senda M, Fujii S, Kurihara Y, Gunji R, et al. Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT). J Diabetes Investig. 2020;11(4):906–16.CrossRefPubMedPubMedCentral

31.

Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, the UTOPIA study investigators, et al. Rationale, design, and baseline characteristics of the UTOPIA trial for preventing diabetic atherosclerosis using an SGLT2 inhibitor: a prospective, randomized, open-label, parallel-group comparative study. Diabetes Ther. 2017;8:999–1013. https://doi.org/10.1007/s13300-017-0292-1.CrossRefPubMedPubMedCentral

32.

Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, the UTOPIA study investigators, et al. Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study. Cardiovasc Diabetol. 2020;19:110. https://doi.org/10.1186/s12933-020-01079-4.CrossRefPubMedPubMedCentral

33.

Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, on behalf of the UTOPIA study investigators, et al. Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial. Cardiovasc Diabetol. 2021;20(1):4. https://doi.org/10.1186/s12933-020-01206-1.CrossRefPubMedPubMedCentral

34.

Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol. 2018;14(2):99–114. https://doi.org/10.1038/nrendo.2017.173.CrossRefPubMed

35.

Sun DQ, Jin Y, Wang TY, Zheng KI, Rios RS, Zhang HY, et al. MAFLD and risk of CKD. Metabolism. 2021;115: 154433.CrossRefPubMed

36.

Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32:1737–42.CrossRefPubMedPubMedCentral

37.

Bhole V, Choi JW, Kim SW, de Vera M, Choi H. Serum uric acid levels and the risk of type 2 diabetes: a prospective study. Am J Med. 2010;123:957–61.CrossRefPubMedPubMedCentral

38.

Lv Q, Meng XF, He FF, Chen S, Su H, Xiong J, et al. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS ONE. 2013;8:e56864.CrossRefPubMedPubMedCentral

39.

Chino Y, Samukawa Y, Sakai S, Nakai Y, Yamaguchi J, Nakanishi T, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014;35:391–404.CrossRefPubMedPubMedCentral

40.

Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Canagliflozin DIA 2001 Study Group, et al. Dose-ranging effects of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35:1232–8.CrossRefPubMedPubMedCentral

41.

Lawler PR, Liu H, Frankfurter C, Lovblom LE, Lytvyn Y, Burger D, et al. Changes in cardiovascular biomarkers associated with the sodium–glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin in patients with chronic kidney disease and type 2 diabetes. Diabetes Care. 2021;44(3):e45–7.CrossRefPubMed

42.

O’Neill J, Fasching A, Pihl L, Patinha D, Franzen S, Palm F. Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol. 2015;309:F227–34.CrossRefPubMed

43.

Bessho R, Takiyama Y, Takiyama T, Kitsunai H, Takeda Y, Sakagami H, et al. Hypoxia-inducible factor-1alpha is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy. Sci Rep. 2019;9:14754.CrossRefPubMedPubMedCentral

44.

Terami N, Ogawa D, Tachibana H, Hatanaka T, Wada J, Nakatsuka A, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One. 2014;9(6):e100777.CrossRefPubMedPubMedCentral

45.

Shin SJ, Chung S, Kim SJ, Lee EM, Yoo YH, Kim JW, et al. Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS One. 2016;11(11):e0165703.CrossRefPubMedPubMedCentral

46.

Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999;10:610–9.CrossRefPubMed

47.

Fink J, Blahut S, Reddy M, Light P. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis. 2001;37:348–55.CrossRefPubMed

48.

Yamamoto T, Miyazaki M, Nakayama M, Yamada G, Matsushima M, Sato M, et al. Impact of hemoglobin levels on renal and non-renal clinical outcomes difers by chronic kidney disease stages: the Gonryo study. Clin Exp Nephrol. 2016;20:595–602.CrossRefPubMed

Titel: Changes in serum levels of liver-related parameters, uric acid, and hemoglobin in patients with type 2 diabetes mellitus under treatment with tofogliflozin—a post-hoc analysis of the UTOPIA study
verfasst von: Naoto Katakami
Tomoya Mita
Yasunori Sato
Hirotaka Watada
Iichiro Shimomura
Publikationsdatum: 10.02.2024
Verlag: Springer Nature Singapore
Erschienen in: Diabetology International
Print ISSN: 2190-1678
Elektronische ISSN: 2190-1686
DOI: https://doi.org/10.1007/s13340-024-00693-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen